NCT05334576 (CRIZ) is a NA clinical trial of Crizanlizumab in Sickle Cell Disease, sponsored by Andria Ford.

Who is sponsoring NCT05334576?

NCT05334576 is sponsored by Andria Ford.

What drugs are being tested in NCT05334576?

Interventions in NCT05334576: Crizanlizumab.

What condition does NCT05334576 study?

NCT05334576 studies Sickle Cell Disease.

Is NCT05334576 still recruiting?

NCT05334576 is currently status unknown. Last updated 6 March 2023.

Last reviewed 2023-03-06 · How we verify

NCT05334576: CRIZ

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of Crizanlizumab for Prevention of Silent Cerebral Infarcts in SCA

Status unknown NA Last updated 6 March 2023

What this trial tests

NA trial testing Crizanlizumab in Sickle Cell Disease in 31 participants. Status unknown.

Timeline

1 August 2022

Primary endpoint
1 July 2024

1 July 2025

Quick facts

Lead sponsor	Andria Ford
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	prevention
Enrollment	31
Start date	1 August 2022
Primary completion	1 July 2024
Estimated completion	1 July 2025
Sites	1 location across United States

Drugs / interventions tested

Crizanlizumab (CRIZANLIZUMAB) — full drug profile →

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →

Sponsor

Andria Ford

Who can join

16 and older, any sex, with Sickle Cell Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In this prospective, single-arm, open-label, imaging and treatment study, the investigator will test the hypothesis that crizanlizumab will prevent the progression of silent cerebral infarcts in patients with sickle cell disease. Study participants will undergo brain MRI before initiation of crizanlizumab and at 6 and 30 months after starting crizanlizumab infusions. The crizanlizumab cohort will be compared to a matched, observational cohort of patients not receiving crizanlizumab.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Current and Future Therapeutics for Treating Patients with Sickle Cell Disease.
Barak M, Hu C, Matthews A, Fortenberry YM. · · 2024 · cited 14× · PMID 38786070 · DOI 10.3390/cells13100848
Managing the Cerebrovascular Complications of Sickle Cell Disease: Current Perspectives.
Light J, Boucher M, Baskin-Miller J, Winstead M. · · 2023 · cited 13× · PMID 37082003 · DOI 10.2147/jbm.s383472
Stroke Prevention and Treatment for Youth with Sickle Cell Anemia: Current Practice and Challenges and Promises for the Future.
Creary S, Chung MG, Villella AD, Lo WD. · · 2024 · PMID 39304580 · DOI 10.1007/s11910-024-01372-9

Verify or expand the search:

Other trials of Crizanlizumab

Trials testing the same drug.

NCT06439082 — A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult · Phase 3 · recruiting
NCT05469828 — Crizanlizumab Improves Tissue Oxygen Supply Demand Matching in Patients With Sickle Cell Anemia · Phase 1, PHASE2 · not yet recruiting
NCT05020873 — Prospective, Observational Study in Sickle Cell Disease Patients on Crizanlizumab Treatment in Middle East Countries and · terminated
NCT05494541 — Characteristics of Patients With Sickle Cell Disease · completed
NCT04657822 — Rollover Study for Patients With Sickle Cell Disease Who Have Completed a Prior Novartis-Sponsored Crizanlizumab Study · Phase 4 · recruiting

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05334576 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Andria Ford
Last refreshed: 6 March 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05334576.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing